科前生物 (688526.SH) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	932.1M	949.7M	941.9M	1.1B	1.0B
Cost of Revenue	311.9M	313.7M	341.4M	296.9M	264.2M
Gross Profit	620.2M	636.1M	600.5M	767.1M	737.0M
Operating Expenses
R&D Expense	100.2M	96.4M	86.1M	88.5M	102.7M
SG&A Expense	—	—	—	—	—
General & Admin Expense	58.9M	59.8M	61.6M	67.0M	66.8M
Selling & Marketing Expense	100.1M	105.2M	114.0M	154.8M	159.9M
Other Expenses	—	—	—	—	—
Total Operating Expenses	214.4M	210.7M	206.4M	250.9M	272.8M
Cost and Expenses	526.4M	524.4M	547.8M	547.8M	537.0M
Operating Income (EBIT)	447.6M	483.1M	438.8M	459.1M	466.7M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	446.2M	481.5M	438.1M	457.6M	466.6M
Income Tax Expense	58.3M	64.6M	56.6M	62.0M	57.5M
Bottom Line
Net Income	389.7M	418.7M	382.4M	395.9M	409.5M
Earnings from Cont. Ops	387.8M	416.9M	381.5M	395.6M	409.1M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	389.7M	418.7M	382.4M	395.9M	409.5M
Per Share
Basic EPS	CN¥0.83	CN¥0.90	CN¥0.82	CN¥0.85	CN¥0.88
Diluted EPS	CN¥0.83	CN¥0.90	CN¥0.82	CN¥0.85	CN¥0.88
Revenue Per Share	CN¥2.00	CN¥2.04	CN¥2.02	CN¥2.28	CN¥2.15
Shares
Basic Shares Outstanding	466.1M	465.2M	466.3M	465.8M	465.4M
Diluted Shares Outstanding	466.1M	465.2M	466.3M	465.8M	465.4M
Profitability Metrics
EBITDA	—	595.4M	547.4M	572.6M	563.7M
D&A	—	112.2M	108.6M	113.5M	96.9M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026